Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX combined with stereotactic radiotherapy for unresectable locally advanced pancreatic cancer
NL-OMON27030Unknown
- Sponsor
- Foundation for Liver and Gastrointestinal Research
- Start
- Dec 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of folinic acid, fluorouracil, irinotecan and oxaliplatin in pancreatic cancer (PC), sponsored by Foundation for Liver and Gastrointestinal Research. Primary endpoint: overall survival. Status: unknown.
02
Drugs
folinic acidfluorouracilirinotecanoxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON27030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27030.